Abstract

The University of California, Davis (UCD) component (Project I) of this Program Project will be to follow a systematic approach of HIV-1 vaccine development by comparing the immunogenicity and toxicity in guinea pigs and rhesus monkeys of inactivated whole virus and recombinant DNA viral products.
The specific aims of Project I (UCD) are: 1) to optimize and standardize conditions for HIV-1 production, purification and inactivation on 10 selected strains of HIV-1 (from Project II-University of California, San Francisco), 2) to assess the immunogenicity and toxicity of whole inactivated HIV and indivdual recombinant viral antigens (from Project III - Chiron Corporation) in guinea pigs and rhesus macaques. Strain-specific humoral and cellular immune responses to the 10 selected HIV-1 isolates will be evaluated, 3) to assess cross-protection from SIV infection and disease in rhesus macaques, immunized with selected HIV strains or antigens, 4) to genetically engineer non-infectious HIV pol gene deletion mutants as candidate whole-virus vaccines and 5) to express HIV-1 envelope glycoproteins and core protein in hybrid vaccinia vectors and infect autologous cell lines as targets for measuring T cell responses in immunized rhesus monkeys.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI026471-01
Application #
3818878
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618

  Publications

Serrano, D; Becker, K; Cunningham-Rundles, C et al. (2000) Characterization of the T cell receptor repertoire in patients with common variable immunodeficiency: oligoclonal expansion of CD8(+) T cells. Clin Immunol 97:248-58
Gardner, M; Rosenthal, A; Jennings, M et al. (1995) Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11:843-54
Gardner, M B; Rosenthal, A; Jennings, M et al. (1994) Passive immunization of macaques against SIV infection. J Med Primatol 23:164-74
Dumitrescu, O; Kalish, M L; Kliks, S C et al. (1994) Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. J Infect Dis 169:281-8
Barnett, S W; Murthy, K K; Herndier, B G et al. (1994) An AIDS-like condition induced in baboons by HIV-2. Science 266:642-6
Giavedoni, L D; Planelles, V; Haigwood, N L et al. (1993) Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 67:577-83
Montefiori, D C; Graham, B S; Kliks, S et al. (1992) Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol 12:429-39
Popov, J; McGraw, T; Hofmann, B et al. (1992) Acute lymphoid changes and ongoing immune activation in SIV infection. J Acquir Immune Defic Syndr 5:391-9
Giavedoni, L D; Jones, L; Gardner, M B et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A 89:3409-13
Planelles, V; Haigwood, N L; Marthas, M L et al. (1991) Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses 7:889-98

Showing the most recent 10 out of 23 publications